Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

Wang,Xinzhao; Song,Hongkuan; Yu,Qian; Liu,Qi; Wang,Leilei; Liu,Zhaoyun; Yu,Zhiyong

doi:10.3892/or.2014.3665

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

Authors:
- Xinzhao Wang
- Hongkuan Song
- Qian Yu
- Qi Liu
- Leilei Wang
- Zhaoyun Liu
- Zhiyong Yu
View Affiliations

Affiliations: School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China, Juxian Hospital of Traditional Chinese Medicine, Rizhao, Shandong 276500, P.R. China, Department of Biology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China
Published online on: December 11, 2014 https://doi.org/10.3892/or.2014.3665
Pages: 526-532
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging results in the treatment of TNBC, even though most of these tumors overexpress EGFR. In the present study, we used recombinant human p53 adenovirus (Ad-p53) and EGFR inhibitor gefitinib to treat the TNBC cell line MDA-MB-468. The combined treatment of gefitinib and Ad-p53 synergistically inhibited the proliferation of MDA-MB-468 cells; it restrained colony formation, enhanced cellular apoptosis and arrested the cell cycle in vitro, and decreased tumor burden of xenografts in nude mice. Western blot analysis revealed that Ad-p53 and gefitinib in combination significantly downregulated the phosphorylation of protein kinase B (p-Akt) and upregulated caspase-9 and cleaved caspase-3, while there were minimal effects on the expression of extracellular signal-regulated kinase (ERK) and phosphorylation of ERK (p-ERK). These results suggest that Ad-p53 may block the PI3K/Akt pathway rather than the Raf/MEK/ERK pathway. Importantly, wild-type p53 was able to reverse the drug resistance of MDA-MB-468 cells to gefitinib through inactivation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. The apoptotic activity induced by this combined treatment may be regulated by caspase cascade-dependent activation.

View Figures

View References

1	Podo F, Buydens LM, Degani H, et al: Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
2	Herold CI and Anders CK: New targets for triple-negative breast cancer. Oncology. 27:846–854. 2013.PubMed/NCBI
3	Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol. 28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
4	Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the ‘triple-negative’ phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 116:317–328. 2009. View Article : Google Scholar
5	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
6	Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
7	von Minckwitz G, Jonat W, Fasching P, et al: A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat. 89:165–172. 2005. View Article : Google Scholar : PubMed/NCBI
8	Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
9	Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol. 23:5323–5333. 2005. View Article : Google Scholar : PubMed/NCBI
10	Janmaat ML and Giaccone G: Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist. 8:576–586. 2003. View Article : Google Scholar : PubMed/NCBI
11	Normanno N, De Luca A, Maiello MR, et al: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 207:420–427. 2006. View Article : Google Scholar : PubMed/NCBI
12	Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R and Colomer R: An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med. 20:3–10. 2007.PubMed/NCBI
13	Vousden KH and Lu X: Live or let die: the cell’s response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
14	Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
15	Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
16	Grob TJ, Heilenkötter U, Geist S, et al: Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat. 134:561–567. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 464:999–1005. 2010. View Article : Google Scholar : PubMed/NCBI
19	Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL and Harari PM: p53 modulates acquired resistance to EGFR inhibitors and radiation. Cancer Res. 71:7071–7079. 2011. View Article : Google Scholar : PubMed/NCBI
20	Brand K, Klocke R, Possling A, Paul D and Strauss M: Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther. 6:1054–1063. 1999. View Article : Google Scholar : PubMed/NCBI
21	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
22	Guida E, Bisso A, Fenollar-Ferrer C, et al: Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res. 68:6550–6558. 2008. View Article : Google Scholar : PubMed/NCBI
23	Selivanova G and Wiman KG: Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 26:2243–2254. 2007. View Article : Google Scholar : PubMed/NCBI
24	Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH and Segall JE: Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 18:519–527. 2012. View Article : Google Scholar : PubMed/NCBI
25	Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012.PubMed/NCBI
26	Bianco R, Shin I, Ritter CA, et al: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22:2812–2822. 2003. View Article : Google Scholar : PubMed/NCBI
27	Yi YW, Hong W, Kang HJ, et al: Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer. J Cell Mol Med. 17:648–656. 2013. View Article : Google Scholar : PubMed/NCBI
28	Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR and Sun SY: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther. 6:2029–2038. 2007. View Article : Google Scholar : PubMed/NCBI
29	McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar
30	Zwang Y, Sas-Chen A, Drier Y, et al: Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell. 42:524–535. 2011. View Article : Google Scholar : PubMed/NCBI
31	Bouali S, Chrétien AS, Ramacci C, et al: P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther. 16:498–507. 2009. View Article : Google Scholar : PubMed/NCBI
32	Kojima K, Konopleva M, Samudio IJ, et al: Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 67:3210–3219. 2007. View Article : Google Scholar : PubMed/NCBI
33	Chang GC, Yu CT, Tsai CH, et al: An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol. 600:37–44. 2008. View Article : Google Scholar : PubMed/NCBI
34	Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH and Choi YH: β-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther. 22:184–192. 2014. View Article : Google Scholar
35	Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ and Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res. 2:1665–1671. 1996.PubMed/NCBI
36	Lang FF, Bruner JM, Fuller GN, et al: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 21:2508–2518. 2003. View Article : Google Scholar : PubMed/NCBI
37	Schuler M, Herrmann R, De Greve JL, et al: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol. 19:1750–1758. 2001.PubMed/NCBI
38	Buller RE, Runnebaum IB, Karlan BY, et al: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9:553–566. 2002. View Article : Google Scholar : PubMed/NCBI
39	Pan JJ, Zhang SW, Chen CB, et al: Effect of recombinant adenovirus- p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol. 27:799–804. 2009. View Article : Google Scholar